Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      OA03.06 - CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

      15:02 - 15:12  |  Presenter: Bob T. Li

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

      Presenter: Alexander Spira

      • Abstract

      Loading...

    • +

      EP08.02-125 - Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer

      Presenter: Paul Stockhammer

      • Abstract

      Loading...

  • +

    P1.10 - Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

    • 17:00 - 19:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: Regular Poster
    • Track: Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy
    • +

      P1.10-01 - Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)

      Presenter: Aarthi Gopinathan

      • Abstract

      Loading...